With Al­ler­gan's ri­val on the reg­u­la­to­ry ropes, Ab­b­Vie posts more promis­ing late-stage da­ta for elagolix

Ab­b­Vie picked a good day to un­veil an­oth­er pos­i­tive set of late-stage da­ta from their uter­ine fi­broid pro­gram for elagolix, now on the mar­ket as Orilis­sa for a dif­fer­ent in­di­ca­tion.

Just hours af­ter Al­ler­gan re­vealed that their ap­pli­ca­tion for a ri­val ther­a­py had been hit with a re­jec­tion let­ter from the FDA, the Ab­b­Vie team says their Phase III ELARIS UF-EX­TEND ex­ten­sion study of elagolix hit a clin­i­cal re­sponse rate of 88%. That comes on top of two clear­ly up­beat Phase III read­outs show­ing a high rate of re­spons­es, de­fined by a sig­nif­i­cant drop in men­stru­al blood loss.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.